{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T21:27:04Z","timestamp":1787174824055,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007923","name":"University of Wisconsin-Madison Carbone Cancer Center","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.adro.2026.102142","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:35:44Z","timestamp":1784180144000},"page":"102142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporally-Modulated Pulsed Radiation Therapy for Large-Volume Reirradiation of Recurrent Meningioma"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2429-1066","authenticated-orcid":false,"given":"Bradley","family":"Eckelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Burr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankush","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Tom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2026.102142_bib0001","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0002","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0003","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","article-title":"Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Nabors","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.adro.2026.102142_bib0004","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ijrobp.2024.10.034","article-title":"Radiation therapy for meningiomas - where do we stand and what's on the horizon?","volume":"121","author":"Ehret","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102142_bib0005","unstructured":"National Library of Medicine. Phase II trial of SMO\/AKT\/ NF2\/CDK inhibitors in progressive meningiomas with SMO\/ AKT\/ NF2\/CDK pathway mutations. Accessed June 25, 2026. https:\/\/clinicaltrials.gov\/study\/NCT02523014"},{"key":"10.1016\/j.adro.2026.102142_bib0006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/neuonc\/noab118","article-title":"Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: Phase II trial results","volume":"24","author":"Bi","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0007","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","article-title":"Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas","volume":"13","author":"Brastianos","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.adro.2026.102142_bib0008","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.23803","article-title":"Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas","volume":"113","author":"Chamberlain","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2026.102142_bib0009","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2015.61.6490","article-title":"Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005","volume":"33","author":"Ji","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/neuonc\/nor044","article-title":"Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma","volume":"13","author":"Johnson","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0011","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0012","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: A retrospective series","volume":"109","author":"Lou","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.adro.2026.102142_bib0013","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4103\/sni.sni_264_17","article-title":"Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review","volume":"9","author":"Franke","year":"2018","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.adro.2026.102142_bib0014","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: Results from the phase II CEVOREM trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2026.102142_bib0015","first-page":"vdac123","article-title":"A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma","volume":"4","author":"Kumthekar","year":"2022","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.adro.2026.102142_bib0016","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma","volume":"30","author":"Kurz","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2026.102142_bib0017","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ijrobp.2024.07.003","article-title":"A prospective, phase II study of 177Lu-Dotatate in patients with surgery- and radiation-refractory meningioma: Results of the WHO grade II\/III cohort","volume":"120","author":"Merrell","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102142_bib0018","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.120.249607","article-title":"Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual patient data meta-analysis","volume":"62","author":"Mirian","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.adro.2026.102142_bib0019","unstructured":"National Library of Medicine. 177Lu-DOTATATE for recurrent meningioma: A randomized phase II study. Accessed June 25, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06326190"},{"key":"10.1016\/j.adro.2026.102142_bib0020","article-title":"TIP-11. MOMENTUM-1: A multicenter, randomized, open-label, phase 2 study of [177Lu]Lu-DOTA-TATE in adults with progressive grade 1-3 meningioma (RTOG 3523)","volume":"27","author":"Kurz","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.14338\/IJPT-18-00045.1","article-title":"Clinical outcomes of recurrent intracranial meningiomas treated with proton beam reirradiation","volume":"5","author":"Imber","year":"2019","journal-title":"Int J Part Ther"},{"issue":"1","key":"10.1016\/j.adro.2026.102142_bib0022","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13014-018-1026-x","article-title":"Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma","volume":"13","author":"El Shafie","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0023","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/0284186X.2023.2241994","article-title":"Proton therapy re-irradiation provides promising clinical results in recurrent brain meningioma","volume":"62","author":"Scartoni","year":"2023","journal-title":"Acta Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0024","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-018-03011-z","article-title":"Large volume re-irradiation for recurrent meningioma with pulsed reduced dose rate radiotherapy","volume":"141","author":"Witt","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.adro.2026.102142_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1259\/bjr\/15764945","article-title":"On the possible increase in local tumour control probability for gliomas exhibiting low dose hyper-radiosensitivity using a pulsed schedule","volume":"80","author":"Tom\u00e9","year":"2007","journal-title":"Br J Radiol"},{"key":"10.1016\/j.adro.2026.102142_bib0026","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ijrobp.2020.06.020","article-title":"Pulsed reduced dose rate radiotherapy in conjunction with bevacizumab or bevacizumab alone in recurrent high-grade glioma: Survival outcomes","volume":"108","author":"Bovi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102142_bib0027","article-title":"Pulsed reduced-dose rate re-irradiation for patients with recurrent grade 2 gliomas","volume":"6","author":"Harari","year":"2024","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.adro.2026.102142_bib0028","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/j.ijrobp.2023.06.946","article-title":"Pulsed reduced dose rate re-irradiation for recurrent grade 4 gliomas: A retrospective analysis of safety and efficacy","volume":"117","author":"Morris","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102142_bib0029","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ijrobp.2009.11.058","article-title":"Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy","volume":"79","author":"Adkison","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102142_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110271","article-title":"Re-irradiation for recurrent intracranial meningiomas: Analysis of clinical outcomes and prognostic factors","volume":"195","author":"Desideri","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0031","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noaf009","article-title":"Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design","volume":"27","author":"Kotecha","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.adro.2026.102142_bib0032","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijrobp.2018.05.011","article-title":"Radiologic response and disease control of recurrent intracranial meningiomas treated with reirradiation","volume":"102","author":"Lin","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.102142_bib0033","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32124-8","article-title":"Hypofractionated stereotactic radiotherapy for patients with intracranial meningiomas: Impact of radiotherapy regimen on local control","volume":"8","author":"Meniai-Merzouki","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.adro.2026.102142_bib0034","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11060-021-03711-z","article-title":"Outcomes of salvage radiation for recurrent world health organization grade II meningiomas: A retrospective cohort study","volume":"152","author":"Momin","year":"2021","journal-title":"J Neurooncol"},{"key":"10.1016\/j.adro.2026.102142_bib0035","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jocn.2012.01.023","article-title":"Reirradiation of recurrent meningioma","volume":"19","author":"Wojcieszynski","year":"2012","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.adro.2026.102142_bib0036","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00259-025-07336-6","article-title":"SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: Analysis of safety, efficacy and prognostic factors","volume":"53","author":"Hasenauer","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109426001491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109426001491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:43:50Z","timestamp":1787172230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109426001491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2452109426001491"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2026.102142","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporally-Modulated Pulsed Radiation Therapy for Large-Volume Reirradiation of Recurrent Meningioma","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2026.102142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102142"}}